Honorary Fellows are elected for life by the British Pharmacological Society in recognition of sustained excellence and leadership in science, healthcare, and public service.
The Honorary Fellowship includes Nobel Laureates, international prize-winners, long-standing members of the Society, and those who have advanced the disciplines of Pharmacology, Clinical Pharmacology and Therapeutics through research, leadership and contribution to the British Pharmacological Society.
Find out more and nominate individuals for Honorary Fellowship.
This Directory has been created to increase the visibility of our Honorary Fellows and their contributions, and to support networking by providing a useful resource for members to connect with Honorary Fellows with similar areas of interest.
Here you can find profiles of each Honorary Fellow, including information on their institutional affiliation, year elected, primary professional setting, Affinity Group membership, along with a short biography.
Please click the magnifying glass icon to begin any searches.
After qualifying in medicine at University College London, and with a MSc in pharmacology, I moved to Oxford as Research Fellow in the Department of Pharmacology, later becoming University Lecturer and Medical Sciences Fellow at Lincoln College.
Medical School and MD in Freiburg, Germany (1963-1969; Stretch-induced automaticity in primate myocardium)After internship in Berlin, postdoc and ‘Habilitation’ in Pharmacology at the University of Kiel (1979: Relationship between shape of the cardiac action potential and contractile force).
Steve Rees is Senior Vice-President of Discovery Sciences at AstraZeneca with responsibility for a range of drug discovery platforms including genomics, functional genomics, small molecule hit discovery and lead optimisation, oligonucleotide discovery and gene editing, for projects for all AstraZeneca therapy areas.
Jim trained in pharmacology under Humphrey Rang in WDM Paton’s department, where they discovered a new kind of drug antagonism, characterised by increased block when certain antagonists were co-administered with agonist.
Professor Dame Nancy Rothwell, FRS, is President and Vice-Chancellor of The University of Manchester, the first woman to lead The University of Manchester or either of its two predecessor institutions, and Professor of Physiology.